ClinicalTrials.gov record
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

A Study on the Immune Response and Safety of an Adjuvanted Human Papillomavirus Vaccine When Given to Healthy Women 16 to 26 Years of Age

ClinicalTrials.gov ID: NCT05496231

Public ClinicalTrials.gov record NCT05496231. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 11, 2026, 3:37 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1/2 Randomized, Observer-blinded, Multi-country Study to Evaluate Safety and Immunogenicity of Investigational Adjuvanted Human Papillomavirus Vaccine in Females (16 to 26 Years of Age)

Study identification

NCT ID
NCT05496231
Recruitment status
Completed
Study type
Interventional
Phase
Phase 1, Phase 2
Lead sponsor
GlaxoSmithKline
Industry
Enrollment
1,080 participants

Conditions and interventions

Interventions

  • Gardasil 9 Biological
  • HPV9 High formulation Biological
  • HPV9 Low formulation Biological
  • HPV9 Medium formulation Biological

Biological

Eligibility (public fields only)

Age range
16 Years to 26 Years
Sex
Female
Healthy volunteers
Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 21, 2022
Primary completion
Feb 22, 2024
Completion
Feb 24, 2024
Last update posted
Feb 2, 2025

2022 – 2024

United States locations

U.S. sites
39
U.S. states
21
U.S. cities
36
Facility City State ZIP Site status
GSK Investigational Site San Diego California 92103-6204
GSK Investigational Site San Diego California 92120
GSK Investigational Site Wheat Ridge Colorado 80033
GSK Investigational Site Coral Gables Florida 33134
GSK Investigational Site Kissimmee Florida 34741
GSK Investigational Site Miami Florida 33125
GSK Investigational Site North Miami Beach Florida 33162
GSK Investigational Site Pompano Beach Florida 33060
GSK Investigational Site Sarasota Florida 34239
GSK Investigational Site Atlanta Georgia 30328
GSK Investigational Site Evansville Indiana 47712
GSK Investigational Site South Bend Indiana 46617
GSK Investigational Site Topeka Kansas 66606
GSK Investigational Site Wichita Kansas 67205
GSK Investigational Site Lexington Kentucky 40509
GSK Investigational Site Covington Louisiana 70433
GSK Investigational Site Elkridge Maryland 21075
GSK Investigational Site Saginaw Michigan 48602
GSK Investigational Site Jefferson City Missouri 65109
GSK Investigational Site Las Vegas Nevada 89102
GSK Investigational Site Albuquerque New Mexico 87102
GSK Investigational Site Raleigh North Carolina 27612
GSK Investigational Site Columbus Ohio 43213
GSK Investigational Site Norman Oklahoma 73072
GSK Investigational Site North Charleston South Carolina 29405
GSK Investigational Site Chattanooga Tennessee 37404
GSK Investigational Site Carrollton Texas 75010
GSK Investigational Site Corpus Christi Texas 78412
GSK Investigational Site Dallas Texas 75251
GSK Investigational Site Fort Worth Texas 76104
GSK Investigational Site Houston Texas 77065
GSK Investigational Site Humble Texas 77338
GSK Investigational Site Humble Texas 77346
GSK Investigational Site Irving Texas 75062
GSK Investigational Site San Antonio Texas 78229
GSK Investigational Site Tomball Texas 77375
GSK Investigational Site West Jordan Utah 84088
GSK Investigational Site Norfolk Virginia 23502
GSK Investigational Site Norfolk Virginia 68701

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 29 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05496231, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 2, 2025 · Synced May 11, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05496231 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →